A controlled study of hepatitis C transmission by organ transplantation. The New England Organ Bank Hepatitis C Study Group

TitleA controlled study of hepatitis C transmission by organ transplantation. The New England Organ Bank Hepatitis C Study Group
Publication TypeJournal Article
Year of Publication1995
AuthorsPereira BJ, Wright TL, Schmid CH, Levey AS
JournalLancet
Volume345
Issue8948
Pagination484 - 7
Date Published45689
Type of ArticleClinical Trial Controlled Clinical Trial Research Support, Non-U.S. Gov't
ISSN0140-6736 (Print) 0140-6736 (Linking)
Accession Number7532254
KeywordsAdult, Cadaver, Enzyme-Linked Immunosorbent Assay, Female, Follow-Up Studies, Graft Survival, Hepacivirus / *immunology, Hepatitis Antibodies / *analysis, Hepatitis C / *transmission, Hepatitis C Antibodies, Humans, Male, Middle Aged, Organ Transplantation / *adverse effects / mortality, Tissue Donors
Abstract

Hepatitis C virus (HCV) can be transmitted by transplantation of cadaver organs from donors with antibody to HCV (anti-HCV); therefore, transplantation of organs from anti-HCV positive donors to anti-HCV-negative recipients has been discouraged. We have looked at outcomes in recipients of organs from anti-HCV positive and negative donors to determine whether this advice is well-founded. Stored sera from 716 consecutive cadaver organ donors procured by the New England Organ Bank between 1986 and 1990 were tested for anti-HCV by a first-generation ELISA (ELISA1); 13 (1.8%) were positive. 29 recipients who received organs from these donors were the study group. 37 donors were randomly selected from 703 ELISA1-negative cadaver organ donors. 74 recipients of organs from these 37 donors were the control group. Clinical records were reviewed and recipient sera were tested for anti-HCV with a second-generation ELISA (ELISA2), and HCV RNA was tested for by polymerase chain reaction. Median post-transplant follow-up was 42 and 49 months for study and control groups. Post-transplantation prevalence of anti-HCV and HCV RNA was 67% and 96% among recipients from anti-HCV-positive donors, and 20% and 18% among recipients from anti-HCV-negative donors (p

Alternate JournalLancet
Notify Library Reference ID1262

Related Incidents